JPMorgan upgrades Replimune stock rating on FDA resubmission path

Key facts

• JPMorgan upgraded Replimune's stock rating.
• The upgrade is based on Replimune's progress toward an FDA resubmission.
• The upgrade reflects increased confidence in Replimune's regulatory path.

JPMorgan's upgrade of Replimune's stock rating suggests a positive outlook from the investment bank regarding the biotechnology company's ability to navigate the FDA's regulatory process. This move could influence investor sentiment and Replimune's stock performance as it progresses with its drug resubmission.